Clinical Trial: Study of HXN-1013 in Healthy Participants and Participants With Mild-to-Moderate Asthma

U.S., Oct. 29 -- ClinicalTrials.gov registry received information related to the study (NCT07900568) titled 'Study of HXN-1013 in Healthy Participants and Participants With Mild-to-Moderate Asthma' on Oct. 21.

Brief Summary: This is a Phase I, randomized, double-blind, placebo-controlled, single ascending dose study evaluating HXN-1013 in healthy participants and participants with mild-to-moderate asthma.

Study Start Date: Dec. 01

Study Type: INTERVENTIONAL

Condition: Health Adults Asthma

Intervention: DRUG: HXN-1013

Participants will receive a single subcutaneous dose of HXN-1013.

DRUG: Placebo

Participants will receive a single subcutaneous dose of placebo.

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Helixon Biotechnology ...